Latest news & insights

Boyds’ Regulatory experts, Dr Patrick Ginty and Dr Sabine Rühle, join AAPS as guest speakers for a Webinar “Highlighting US and European Regulatory Requirements for Gene and Cell Therapy Products”

An article authored by Dr Harriet Gray Stephens MFPM, Pharmaceutical Physician in the Clinical and Medical Affairs team at Boyds, has been published in Cell & Gene Therapy Insights.

The government has announced that the UK is to re-join the EU’s flagship scientific research scheme, Horizon. UK-based scientists and institutions will be able to apply for money from the £81bn (€95bn) fund from today. Associate membership had been agreed as part of the Brexit trade deal when the UK formally left the EU in 2020.

On 05 October, Boyds will be co-hosting a live webinar with Cisiv, discussing how to successfully operationalize real-world data collection alongside expanded access programs.

Boyds is pleased to announce the appointment of regulatory operations and publishing professional Michelle Hackney to lead our new in-house Regulatory Operations offering.

Boyds are excited to announce the expansion of its service offering with the launch of a new in-house regulatory operations service that will enable the company to support the full lifecycle of its clients’ drug development projects.

We are delighted to congratulate Chief Medical Officer at Boyds, Dr Karen Mullen, on being recognised as a Global Fellow in Medicines Development (GFMD) by the Academy of Global Medicines Development Professionals.

Boyds is delighted to announce the appointment of regulatory affairs professional Eric Hardter to our US team.